Codexis, a life sciences tech firm, is focusing on specialized enzymes and ECO Synthesis to replace less efficient chemical processes in drug manufacturing. This shift is promising as commoditized small molecules lose appeal. The company has received a customer manufacturing order and positive CDMO evaluations, indicating market interest. Although recurring commercial demand and larger contracts are yet to be seen, a recent equity offering strengthened Codexis's finances, making its current valuation attractive for investors, leading to a 'Buy' rating.
AMD introduced its Helios rack-scale AI solution, claiming a 30% improvement in inference tokens per dollar compared to Nvidia. The company secured significant AI infrastructure contracts, including a 2GW compute deal with Anthropic and deployments o...
The abrdn Global Infrastructure Income Fund (ASGI) currently trades at a 10.69% premium to its net asset value, well above its usual discount. It offers a strong 10.7% dividend yield, supported by net realized gains, though this reliance could be ris...
Tesla reported record revenues and vehicle deliveries in Q2, showing strong top-line growth across automotive, energy, and services sectors. However, earnings remain under pressure due to increased operating expenses and capital expenditures. The com...
Shiba Inu experienced a massive inflow of about 2.4 trillion SHIB tokens into exchange wallets within 24 hours, coinciding with a price jump from $0.0000042 to $0.0000054. This surge was not caused by a single whale but rather by multiple traders, ma...
Riot Platforms is rated a Buy due to its strategic shift toward AI data center hosting, supported by a significant 2 GW supply deal with AMD that exceeds Riot's planned 1.2 GW expansion. While short-term challenges include declining Bitcoin mining re...
